Literature DB >> 8799475

Molecular cloning and expression of human liver biliverdin-IX beta reductase.

A Komuro1, T Tobe, K Hashimoto, Y Nakano, T Yamaguchi, H Nakajima, M Tomita.   

Abstract

The cDNA encoding for human liver isozyme I of biliverdin-IX beta reductase was cloned from human liver cDNA libraries. The constructed cDNA of 853 bp in length contained an entire reading frame coding 206 amino acid residues. It was found that isozyme 1 of biliverdin-IX beta reductase is identical to human erythrocyte NADPH-flavin reductase recently reported in a communication by Chikuba et al., Biochem. Biophys. Res. Commun., 198, 1170-1176 (1994). We, further, characterized this mRNA by Northern blot analyses of poly(A) RNA from four different human fetal tissues and eight different human adult tissues showed hybridization mainly to liver RNA in fetal tissues and to skeletal muscle and liver RNA in adult tissues. Southern blot analysis indicated that isozyme I of biliverdin-IX beta reductase appeared to be a single copy gene. Insertion of the enzyme-coding sequence into an expression vector pET-3c yielded relatively high amounts of the active enzyme in E. coli. The amino terminal sequence of the recombinant protein was identical to that of native enzyme, indicating that E. coli also removed the N-terminal methionine to produce the mature form. The recombinant and native biliverdin-IX beta reductases were indistinguishable as far as their mobility on SDS-PAGE gel, immunoreactivity and specific activity were concerned.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799475     DOI: 10.1248/bpb.19.796

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

1.  The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding.

Authors:  Giel Hendriks; Remco S Derr; Branislav Misovic; Bruno Morolli; Fabienne M G R Calléja; Harry Vrieling
Journal:  Toxicol Sci       Date:  2015-12-29       Impact factor: 4.849

2.  Diagnosis and clinical management of enzymopathies.

Authors:  Lucio Luzzatto
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Label-free quantitative protein profiling of vastus lateralis muscle during human aging.

Authors:  Laëtitia Théron; Marine Gueugneau; Cécile Coudy; Didier Viala; Astrid Bijlsma; Gillian Butler-Browne; Andrea Maier; Daniel Béchet; Christophe Chambon
Journal:  Mol Cell Proteomics       Date:  2013-11-11       Impact factor: 5.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.